Respiratory syncytial virus poses a significant health threat to older populations worldwide. Recently, clinical trials evaluated the performance of RSV vaccines for adults to reduce severe illness. These vaccines show promising results in preventing hospitalizations and complications. Physicians must understand these findings to guide their patients effectively. Moreover, the disease burden remains high in comorbid populations.
Efficacy of RSV Vaccines for Adults
A recent review analyzed several randomized controlled trials involving older patients. It found that protein subunit vaccines significantly lower the risk of RSV-related hospitalizations. Specifically, efficacy reached over 83% for these serious outcomes. Furthermore, these vaccines prevent severe respiratory illness with 94% efficacy. Consequently, clinicians should consider these options for individuals over sixty years old. However, evidence for younger adults remains quite limited currently. Because of this gap, more research is necessary for younger cohorts.
Safety and Adverse Events
Safety remains a primary concern for any new immunization program. Fortunately, the review indicates that protein subunit vaccines do not increase serious adverse events. Researchers compared these vaccines to placebos and found no significant differences in risk. Similarly, messenger RNA vaccines displayed a high safety profile. They did not increase mortality rates among the study participants. Therefore, the overall risk-to-benefit ratio appears favorable for older populations. Nevertheless, doctors should monitor for rare reactions in clinical practice. This vigilance ensures patient safety during the vaccine rollout.
Frequently Asked Questions
Q1: Do RSV vaccines reduce the risk of death in older adults?
Current evidence suggests that these vaccines do not significantly affect all-cause mortality, despite reducing severe illness and hospitalizations.
Q2: Are mRNA RSV vaccines as safe as protein subunit vaccines?
Yes, studies show that mRNA RSV vaccines do not significantly increase serious adverse events compared to a placebo in older adults.
References
- Moser ITK et al. Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians. Ann Intern Med. 2026 Mar 03. doi: 10.7326/ANNALS-25-05536. PMID: 41771131.
- Centers for Disease Control and Prevention. RSV Vaccination for Adults 60 Years and Older. 2024.
- World Health Organization. Respiratory Syncytial Virus (RSV) Surveillance and Vaccines. 2024.